Precision Medicine for Every Child With Cancer

Launched by AUSTRALIAN & NEW ZEALAND CHILDREN'S HAEMATOLOGY/ONCOLOGY GROUP · Aug 15, 2022

Keywords

ClinConnect Summary

This clinical trial, titled "Precision Medicine for Every Child With Cancer," aims to improve the treatment outcomes for children with various types of cancer, including brain tumors, leukemia, and other solid tumors. The study will focus on using precision medicine, which means tailoring cancer treatment to the specific needs and genetic makeup of each child. By doing this, researchers hope to find the most effective therapies for young patients, especially those whose cancer has come back or is hard to treat.

To participate in this trial, children and young adults up to 25 years old may be eligible, provided they have a life expectancy of more than six weeks and meet other specific requirements. Participants will need consent from a parent or guardian if they are under 18, and they will also be asked to agree to genetic testing, which can help in understanding their cancer better. Throughout the study, families can expect support and guidance as they explore new treatment options designed just for their child’s unique situation.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age \< 18 years Note: Individual patients aged 19 - 25 years old with a pediatric cancer, e.g., neuroblastoma, may be enrolled after discussion with, and at the discretion of, the Study Chair or their delegate.
• • 2. Life expectancy \>6 weeks at time of enrolment
• • 3. Consent i. Signed and dated informed consent for study enrolment from participant aged ≥ 18 years or from parent/guardian of participant aged \<18 years. ii. Separate signed and dated informed consent for understanding the role of germline testing and choice for the return of germline results.